RUBY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Dec 2023 @ 15:49):

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases...

Stats
Today's Volume	755 858
Average Volume	99 535.00
Market Cap	5.16M
EPS	$0 ( 2024-02-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0286
ATR14	$0.00200 (3.51%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-24	Appelhans Dannielle	Sell	10 385	Common Stock
2023-02-01	Cagnoni Pablo J	Sell	8 448	Common Stock
2023-01-31	Appelhans Dannielle	Sell	7 500	Restricted Stock Units
2023-01-31	Appelhans Dannielle	Buy	7 500	Common Stock
2023-02-01	Appelhans Dannielle	Sell	3 878	Common Stock

INSIDER POWER
-13.04
Last 96 transactions
Buy: 4 525 378 \| Sell: 349 777

Volume Correlation

Long: 0.54 (weak)

Short: 0.36 (neutral)

Signal:(87.518) Neutral

Rubius Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rubius Therapeutics Inc Correlation - Currency/Commodity

0.35
( neutral )

0.25
( neutral )

0.00
( neutral )

0.31
( neutral )

0.04
( neutral )

Rubius Therapeutics Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.56

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.56

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.23

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.08

Financial Reports:

No articles found.

Rubius Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Rubius Therapeutics Inc

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.